Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T88318
|
||||
| Former ID |
TTDC00181
|
||||
| Target Name |
Protein kinase C
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Diabetic foot ulcer [ICD9: 707; ICD10: L88-L89] | |||||
| HIV-1 infection [ICD9: 001-139, 042; ICD10: B20-B24] | |||||
| Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
| Melanoma [ICD9: 172; ICD10: C43] | |||||
| Psoriasis [ICD9: 696; ICD10: L40] | |||||
| Parkinson's disease [ICD9: 332; ICD10: G20] | |||||
| Transplant rejection [ICD9: 279.5, 996; ICD10: D89.8, T86] | |||||
| Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10: B01, B02, A60, B00, B27, G05.1, P35.2] | |||||
| BioChemical Class |
Kinase
|
||||
| Target Validation |
T88318
|
||||
| EC Number |
EC 2.7.1.-
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Synthetic hypericin | Drug Info | Phase 3 | Viral infections | [1] |
| AEB07 | Drug Info | Phase 2 | Transplant rejection | [2] | |
| APH-0812 | Drug Info | Phase 2 | HIV-1 infection | [3], [4] | |
| CYCLOPLATAM | Drug Info | Phase 2 | Cancer | [5] | |
| HO/03/03 | Drug Info | Phase 2 | Diabetic foot ulcer | [6] | |
| Staurosporine | Drug Info | Phase 2 | Discovery agent | [7], [8] | |
| AEB701 | Drug Info | Phase 1 | Melanoma | [9] | |
| GCC-1290K | Drug Info | Phase 1 | Parkinson's disease | [10] | |
| SAFINGOL | Drug Info | Phase 1 | Psoriasis | [11], [12] | |
| Rottlerin | Drug Info | Preclinical | Parkinson's disease | [13], [14] | |
| Calphostin C | Drug Info | Terminated | Discovery agent | [15], [16] | |
| Ro-31-8830 | Drug Info | Terminated | Inflammatory disease | [17] | |
| Inhibitor | AEB07 | Drug Info | [2] | ||
| AEB701 | Drug Info | [18] | |||
| APH-0812 | Drug Info | [3], [4] | |||
| Calphostin C | Drug Info | [19] | |||
| CYCLOPLATAM | Drug Info | [20] | |||
| Go6850 | Drug Info | [21] | |||
| Go6976 | Drug Info | [22] | |||
| Ro-31-8830 | Drug Info | [23] | |||
| Rottlerin | Drug Info | [13] | |||
| SAFINGOL | Drug Info | [24] | |||
| Staurosporine | Drug Info | [19] | |||
| Synthetic hypericin | Drug Info | [25] | |||
| Modulator | GCC-1290K | Drug Info | [10] | ||
| HO/03/03 | Drug Info | [26] | |||
| Binder | Selenocompounds | Drug Info | [27] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02448381) Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides). U.S. National Institutes of Health. | ||||
| REF 2 | What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81. | ||||
| REF 3 | Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36. | ||||
| REF 4 | Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. | ||||
| REF 5 | Results of phase II clinical trial of cycloplatam in refractory solid tumors. Vopr Onkol. 2001;47(6):752-6. | ||||
| REF 6 | ClinicalTrials.gov (NCT00926068) Safety and Efficacy of HO/03/03 10?? in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers. U.S. National Institutes of Health. | ||||
| REF 7 | ClinicalTrials.gov (NCT00098956) 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
| REF 8 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 346). | ||||
| REF 9 | Nearly 800 Medicines and Vaccines in Clinical Testing For Cancer Offer New Hope to Patients. Pharmaceutical Research and Manufacturers of America report. 2014. | ||||
| REF 10 | Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34. | ||||
| REF 11 | ClinicalTrials.gov (NCT00084812) Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 12 | A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2484-92. | ||||
| REF 13 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | ||||
| REF 14 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2611). | ||||
| REF 15 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5156). | ||||
| REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004175) | ||||
| REF 17 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001273) | ||||
| REF 18 | Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253. | ||||
| REF 19 | Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. | ||||
| REF 20 | Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73. | ||||
| REF 21 | Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. | ||||
| REF 22 | The protein kinase C inhibitor G?6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5. | ||||
| REF 23 | Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions. 1992 Sep;37(1-2):85-9. | ||||
| REF 24 | The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71. | ||||
| REF 25 | Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8. | ||||
| REF 26 | WO patent application no. 2014,0853,81, Pharmaceutical combinations. | ||||
| REF 27 | Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.